31 Democratic oversight letters analyzed. 15 drug manufacturers named and ranked for the investigations that would open first if Democrats take a chamber in November.
What’s Included:
- Private sector analysis of the most exposed drugmakers, from Merck, Bristol Myers Squibb, and Novartis to Pfizer, Eli Lilly, and Novo Nordisk
- Company exposure profiles with the records investigators are likely to demand
- Ten investigative dossiers, from the secret most-favored-nation drug deals and TrumpRx to PBMs, Medicaid withholding, and public health integrity
- Officials named across HHS, CMS, CDC, FDA, OMB, and OPM
- A sector risk register across pharma, PBMs, payers, providers, and research
- A committee map of which chairs pursue each thread, and how
- Preservation flags, engagement windows, and monitoring priorities